A Case Report of Angioedema and Anaphylactic Shock Induced by Ingestion of Polyethylene Glycol

Permalink
https://escholarship.org/uc/item/2119r9w5

Journal
Clinical Practice and Cases in Emergency Medicine, 4(2)

Authors
Rossi, Amy
Osborn, Lesley

Publication Date
2020

DOI
10.5811/cpcem.2020.3.45218

Copyright Information
Copyright 2020 by the author(s). This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed
A Case Report of Angioedema and Anaphylactic Shock Induced by Ingestion of Polyethylene Glycol

Amy Rossi, MD
Lesley Osborn, MD

University of Texas at Houston, McGovern Medical School, Department of Emergency Medicine, Houston, Texas

Section Editor: Rick A. McPheeters, DO
Submission history: Submitted September 14, 2019; Revision received February 27, 2020; Accepted March 6, 2020
Electronically published April 23, 2020
Full text available through open access at http://escholarship.org/uc/uciem_cpcem
DOI: 10.5811/cpcem.2020.3.45218

Introduction: We report one of few documented cases of a severe anaphylactic reaction with angioedema to polyethylene glycol (PEG).

Case Report: The patient presented 30 minutes after onset of his symptoms and quickly developed hypoxia and hypotension refractory to intramuscular epinephrine, intravenous fluids, methylprednisolone, and supplemental oxygen via non-rebreather mask. He ultimately required intubation, an epinephrine infusion, and admission to the medical intensive care unit.

Discussion: This case depicts a clinical reaction to PEG, a medication rarely implicated in severe anaphylaxis or angioedema.

Conclusion: The allergenic potential of PEG-containing products should be raised, and providers should have a heightened awareness of these potential side effects. [Clin Pract Cases Emerg Med. 2020;4(2):189–192.]

Keywords: Polyethylene glycol; PEG; allergic; angioedema.

INTRODUCTION

Polyethylene glycol (PEG) is a compound found in a variety of products classically viewed as chemically inert substances. In the medical community, it is recognized most frequently as the active ingredient in bowel-cleansing regimens such as Miralax, Go-Lytely, or Half-Lytely. It is also an additive in numerous other medications and substances ranging from intramuscular (IM) depot-provera to antibiotic tablets and ultrasound gel. Upon review of the literature, we present only the second published case of a severe allergic reaction involving both anaphylactic shock and angioedema to PEG, particularly unique in its severity despite typical anaphylaxis treatment. Fourteen cases of anaphylactic shock secondary to substances containing PEG have been reported; however, only one of these was further complicated by angioedema. In the emergency department (ED), this additional complication can drastically change management of patients, necessitating an awareness of the severity of this reaction to this commonly prescribed medication.

CASE REPORT

A 76-year-old obese Caucasian male with past medical history of hypertension controlled with hydrochlorothiazide, chronic obstructive pulmonary disease on ipratropium bromide and albuterol, diabetes mellitus type II on metformin, atrial fibrillation on diltiazem and warfarin, gastroesophageal reflux disorder, and benign prostatic hypertrophy on tamsulosin presented to the ED with acute-onset shortness of breath. On initial examination, the patient was in respiratory distress, unable to speak greater than two-word phrases, with diffuse erythema and associated severe pruritus. He described an acute onset of these symptoms approximately 30 minutes prior to arrival to the ED. On initial evaluation, he gave us a piece of paper on which he had written “polyethylene glycol,” implicating this as the new and only medication or substance he had ingested in the three hours prior to presentation.

At the time of arrival, the patient’s blood pressure (BP) was 177/143 millimeters of mercury (mmHg), heart rate (HR)
DISCUSSION

PEGs are polymers composed of ethylene oxide that are non-ionic and hydrophilic and are thought to be chemically inert. They are commonly used in industry production of medications, medical products, and cosmetics. Given its chemical structure as a large hydrophilic polymer, it is effective as a bowel regimen as it does not readily cross the mucosal surface of the gastrointestinal tract. Due to this inherent quality, the compound has generally been viewed as minimally antigenic or reactive. However, larger PEG polymers (>1000 atomic mass units) have immunogenic properties as they are likely large enough to elicit immune responses. While in general these are poorly absorbed, it has been demonstrated that PEG polymers can be recovered in the urine and would, therefore, be able to elicit immune responses in these subjects.

Of those cases with reported reactions to PEG-containing products, the majority of patients present with simple urticaria or meet criteria of anaphylaxis with greater than two body systems involved. However, more severe reactions involving anaphylactic shock and occurrences of ventricular arrhythmias have been documented. Wenande et al recently reported a summary of the known cases of allergic reactions to PEG-containing products. Of those reported, fewer than 20 patients experienced cardiovascular collapse indicative of anaphylactic shock and only one with co-existing angioedema. All cases reported with discussion of patient management detailed resolution of anaphylactic symptoms and angioedema over the course of hours with recurrent dosing of epinephrine, antihistamines, and steroids.

Our case differed in severity to those cited above, as the patient’s quick decompensation necessitated an escalation...
in treatment. The primary change in management was introduction of continuous IV epinephrine to support BP. Current guidelines support administration of IM epinephrine to stable patients demonstrating anaphylaxis; however, they recommend administration of IV epinephrine if anaphylaxis appears to be severe with an immediate life-threatening manifestation. The recommended starting infusion rate is between 1-4 micrograms per minute. Other treatment modalities remained the same, including steroid dosing and use of H1 (histamine type 1) and H2 antagonists.

The case reported here also presented a potentially difficult endotracheal intubation secondary to the significant angioedema visualized on his initial bedside oropharyngeal exam. It was presumed to be resultant of a histaminergic reaction given the concurrent anaphylaxis, as opposed to a non-histaminergic cause, such as bradykinin-mediated or hereditary angioedema, which would require a different treatment regimen.

The patient was not actively taking angiotensin-converting enzyme inhibitors for hypertension, one of the most implicated substances in bradykinin-mediated angioedema. He had not previously had an allergic reaction or edema of his lips or oropharynx to any other substance per his report. He also had no personal or family history of similar presentations, which makes it unlikely that he suffers from hereditary angioedema.

Histaminergic angioedema is a subtype of angioedema caused by a deep tissue reaction initiated by histamine release from mast cells, and by subsequent immunoglobulin E-mediated complement activation. It causes vasodilation and vascular permeability, typically affecting the perioral and periorbital regions, but can also be seen as a non-pitting edema of the extremities and abdomen. When this reaction localizes to the oropharyngeal structures, endotracheal intubation may become extremely challenging due to severe hypopharyngeal and vocal cord edema.

Studies vary on prevalence of airway obstruction with angioedema; however, in general about 15% of all types of angioedema cases require intubation, and 50% of those needing a definitive airway require cricothyrotomy or tracheostomy. We identified no recent studies with a PubMed search on rates of intubation in histamine-mediated angioedema specifically. Histaminergic angioedema is mediated by the cytokine and histamine activation implicated in anaphylaxis, and the use of antihistamines, steroids, and epinephrine is regarded as the standard of care.

We suspect that the patient was therefore able to tolerate a significant ingestion prior to onset of symptoms, and the amount ingested was likely the cause of his rapid deterioration to anaphylactic shock, despite the appropriate initial management for anaphylaxis. Although the associated side effects of PEGs are commonly restricted to abdominal discomfort, bloating, cramping, and nausea, case reports like this one suggest a need for increased awareness in all specialties that regularly prescribe these medications. Emergency providers should be especially aware of this reported complication of PEG-containing products as rapid identification and resuscitation is key to improving morbidity and mortality in these patients.

The authors attest that their institution requires neither Institutional Review Board approval, nor patient consent for publication of this case report. Documentation on file.

Address for Correspondence: Amy Rossi, MD, University of Texas at Houston, McGovern Medical School, Department of Emergency Medicine, 6431 Fannin St., Houston, TX 77030. Email: Amy.rossi@uth.tmc.edu.

Conflicts of Interest: By the CPC-EM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. The authors disclosed none.

Copyright: © 2020 Rossi et al. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: http://creativecommons.org/licenses/by/4.0/

REFERENCES

1. Shah S, Prematta T, Adkinson NF, et al. Hypersensitivity to polyethylene glycols. J Clin Pharmacol. 2013;53(3):352-5.
2. Wilkerson R. Angioedema in the Emergency department: an evidenced-based review. Emerg Med Pract. 2012;14(11):1-24.
3. Wenande E and Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46(7):907-22.
4. Gachoka D. Polyethylene glycol (PEG)-induced anaphylactic reaction during bowel preparation. ACG Case Rep J. 2015;2(4):216-7.
5. Lewis LM. Angioedema: etiology, pathophysiology, current and emerging therapies. J Emerg Med. 2013;45(5):789-96.
6. Knop K, Hoogenboom R, Fischer D, et al. Poly(ethylene glycol) in drug
delivery; pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49(36):6288-308.

7. Brady CE, DiPalma JA, Morawski SG, et al. Urinary excretion of polyethylene glycol 3350 and sulfate after gut lavage with a polyethylene glycol electrolyte lavage solution. Gastroenterology. 1986;90(6):1914-18.

8. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol. 2006;117(2):391-7.

9. Marsh WM, Bronner MH, Yantis PL. Ventricular ectopy associated with perioral colonic lavage, Gastrointest Endosc. 1986;(32):259-63.

10. ECC Committee and Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005;112 (24):IV1-203.

11. Long BJ, Koyfman A, Gottlieb M. Evaluation and management of angioedema in the emergency department. West J Emerg Med. 2019;20(4):587-600.

12. Depetri F, Tedeschi A, Cugno M. Angioedema and emergency medicine: from pathophysiology to diagnosis and treatment. Eur J Intern Med. 2019;59:8-13.